FOXP1 (EP137) Rabbit Monoclonal Antibody

FOXP1
FOXP1 (EP137) on diffuse large B-cell lymphoma (DLBCL).

FOXP1 (EP137) Rabbit Monoclonal Antibody

Specialties: Hematopathology

Updated: 2017-09-20 09:30:20

Diffuse large B-cell lymphoma (DLBCL) most likely represents different clinicopathologic entities, which are difficult to separate using standard technique.1,2 Diffuse large B-cell lymphoma (DLBCL) can be divided into the subtypes of germinal center B-cell–like (GCB), activated B-cell–like (ABC), and unclassified DLBCL.2-4  The GCB and ABC subtypes have different pathogenetic mechanisms that will impact the development of targeted therapies.3 Despite the robustness of gene expression profiling (GEP) in subclassifying DLBCL, GEP techniques are not applicable to the routine clinical practice due to the substantial time, technological expertise, and scarce resources required. Therefore, it is beneficial for the translational application of the GEP classification into protein expression by tumor cells to be developed through immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded tissues. Different approaches using immunophenotypic algorithms with small panels of antibody biomarkers have been developed to translate the robust information from molecular studies into a routine clinical platform,5-9 using antibodies against CD10, BCL6, MUM1/IRF4, GCET1, FoxP1, LMO2, and BCL2. Therefore, FoxP1 is useful in subclassification of DLBCL and a high cutoff (≥80%) for FoxP1 is needed to achieve high specificity for the ABC subtype.

  1. Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Edition. Geneva: World Health Organization; 2008. Print.
  2. Alizadeh AA, et al. Nature. 2000; 403:503-11.
  3. Rosenwald A, et al. N Engl J Med. 2002; 346:1937-47.
  4. Wright G, et al. Proc Natl Acad Sci USA. 2003; 100:9991-6.
  5. Colomo L, et al. Blood, 2003; 101:78-84.
  6. Hans CP, et al. Blood. 2004; 103:275-82.
  7. Muris JJ, et al. J Pathol, 2006; 208:714-23.
  8. Choi WW, et al. Clin Cancer Res. 2009; 15:5494-5502.
  9. Nyman H, et al. Mod Pathol. 2009; 22:1094-1101.

Specifications


  • Reactivity: paraffin
  • Visualization: nuclear
  • Control: tonsil, lymph node
  • Dilution Range: 1:100-1:500*

Package Inserts


IFU SDS

Ordering Information

For in vitro diagnostic (IVD) use in USA

0.1 mL concentrate350R-24
0.5 mL concentrate350R-25
1 mL concentrate350R-26
1 mL predilute350R-27
7 mL predilute350R-28

For in vitro diagnostic (IVD) use in Canada

0.1 mL concentrate350R-24
0.5 mL concentrate350R-25
1 mL concentrate350R-26
1 mL predilute350R-27
7 mL predilute350R-28

For in vitro diagnostic (IVD) use in Europe

0.1 mL concentrate350R-24
0.5 mL concentrate350R-25
1 mL concentrate350R-26
1 mL predilute350R-27
7 mL predilute350R-28

For research use only (RUO) in Japan

0.1 mL concentrate350R-24-RUO
0.5 mL concentrate350R-25-RUO
1 mL concentrate350R-26-RUO
1 mL predilute350R-27-RUO
7 mL predilute350R-28-RUO

 

To request information on this product in additional countries, please click the button below.

Request More Information